IDEAS home Printed from https://ideas.repec.org/r/eee/jhecon/v47y2016icp20-33.html
   My bibliography  Save this item

Innovation in the pharmaceutical industry: New estimates of R&D costs

Citations

Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
as


Cited by:

  1. Javad Moradpour & Aidan Hollis, 2020. "Patient income and health innovation," Health Economics, John Wiley & Sons, Ltd., vol. 29(12), pages 1795-1803, December.
  2. Gemma Turon & Jason Hlozek & John G. Woodland & Ankur Kumar & Kelly Chibale & Miquel Duran-Frigola, 2023. "First fully-automated AI/ML virtual screening cascade implemented at a drug discovery centre in Africa," Nature Communications, Nature, vol. 14(1), pages 1-11, December.
  3. Manuel Hermosilla, 2021. "Rushed Innovation: Evidence from Drug Licensing," Management Science, INFORMS, vol. 67(1), pages 257-278, January.
  4. Nagesh N. Murthy & Haikady N. Nagaraja & Hossein Rikhtehgar Berenji, 2023. "Managing concurrency in cyclical projects under stochastic task environments: Vaccine development projects during pandemics," Production and Operations Management, Production and Operations Management Society, vol. 32(3), pages 951-971, March.
  5. Ricardo Arcaro & Cássia Rita Pereira da Veiga & Wesley Vieira da Silva & Claudimar Pereira da Veiga, 2021. "Attitude and Purchase Intention to Generic Drugs," IJERPH, MDPI, vol. 18(9), pages 1-16, April.
  6. Adrian Towse;Jimena Ferraro;Jorge Mestre-Ferrandiz, 2017. "Incentives for New Drugs to Tackle Anti-Microbial Resistance," Briefing 001842, Office of Health Economics.
  7. Steffen Nauhaus & Johannes Luger & Sebastian Raisch, 2021. "Strategic Decision Making in the Digital Age: Expert Sentiment and Corporate Capital Allocation," Journal of Management Studies, Wiley Blackwell, vol. 58(7), pages 1933-1961, November.
  8. Farasat A. S. Bokhari & Franco Mariuzzo & Anna Rita Bennato, 2021. "Innovation and growth in the UK pharmaceuticals: the case of product and marketing introductions," Small Business Economics, Springer, vol. 57(1), pages 603-634, June.
  9. Kristopher J. Hult, 2017. "Measuring the Potential Health Impact of Personalized Medicine: Evidence from MS Treatments," NBER Working Papers 23900, National Bureau of Economic Research, Inc.
  10. Hongwei Wang & Yixin Fang & Weili He & Ruizhe Chen & Su Chen, 2022. "Clinical Trials with External Control: Beyond Propensity Score Matching," Statistics in Biosciences, Springer;International Chinese Statistical Association, vol. 14(2), pages 304-317, July.
  11. Shamim S. Mondal & Viswanath Pingali, 2017. "Competition and Intellectual Property Policies in the Indian Pharmaceutical Sector," Vikalpa: The Journal for Decision Makers, , vol. 42(2), pages 61-79, June.
  12. Cyrus Aghamolla & Richard T. Thakor, 2022. "Do Mandatory Disclosure Requirements for Private Firms Increase the Propensity of Going Public?," Journal of Accounting Research, Wiley Blackwell, vol. 60(3), pages 755-804, June.
  13. repec:zbw:fisidp:289610 is not listed on IDEAS
  14. Fumio Teramae & Tomohiro Makino & Yeongjoo Lim & Shintaro Sengoku & Kota Kodama, 2020. "Impact of Research and Development Strategy on Sustainable Growth in Multinational Pharmaceutical Companies," Sustainability, MDPI, vol. 12(13), pages 1-15, July.
  15. Jonathan Dando & Maximilian Lebmeier, 2020. "A novel valuation model for medical intervention development based on progressive dynamic changes that integrates Health Technology Assessment outcomes with early-stage innovation and indication-speci," Journal of Innovation and Entrepreneurship, Springer, vol. 9(1), pages 1-28, December.
  16. Arzi Adbi & Chirantan Chatterjee & Matej Drev & Anant Mishra, 2019. "When the Big One Came: A Natural Experiment on Demand Shock and Market Structure in India's Influenza Vaccine Markets," Production and Operations Management, Production and Operations Management Society, vol. 28(4), pages 810-832, April.
  17. Daniel Tobias Michaeli & Hasan Basri Yagmur & Timur Achmadeev & Thomas Michaeli, 2022. "Value drivers of development stage biopharma companies," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(8), pages 1287-1296, November.
  18. Dosis, Anastasios & Muthoo, Abhinay, 2019. "Experimentation in Dynamic R&D Competition," CRETA Online Discussion Paper Series 52, Centre for Research in Economic Theory and its Applications CRETA.
  19. Yusuke Oh & Koji Takahashi, 2020. "R&D and Innovation: Evidence from Patent Data," Bank of Japan Working Paper Series 20-E-7, Bank of Japan.
  20. Zhili Tian & Haresh Gurnani & Yi Xu, 2021. "Collaboration in Development of New Drugs," Production and Operations Management, Production and Operations Management Society, vol. 30(11), pages 3943-3966, November.
  21. Gamba, Simona & Magazzini, Laura & Pertile, Paolo, 2021. "R&D and market size: Who benefits from orphan drug legislation?," Journal of Health Economics, Elsevier, vol. 80(C).
  22. Branstetter, Lee & Chatterjee, Chirantan & Higgins, Matthew J., 2022. "Generic competition and the incentives for early-stage pharmaceutical innovation," Research Policy, Elsevier, vol. 51(10).
  23. Aysun, Uluc, 2020. "Volatility costs of R&D," European Economic Review, Elsevier, vol. 122(C).
  24. Pooja Thakur-Wernz & Olga Bruyaka, 2017. "Co-evolutionary Perspective on Sourcing Portfolios: Examining Sourcing Choices for Clinical Trials of Bio-pharmaceutical Firms," Management International Review, Springer, vol. 57(6), pages 909-946, December.
  25. Snyder, Christopher M. & Hoyt, Kendall & Gouglas, Dimitrios, 2023. "An optimal mechanism to fund the development of vaccines against emerging epidemics," Journal of Health Economics, Elsevier, vol. 91(C).
  26. Amiya K. Chakravarty, 2021. "The outsourcing conundrum: Misappropriation of intellectual property in supply chains," Naval Research Logistics (NRL), John Wiley & Sons, vol. 68(2), pages 229-240, March.
  27. Banerjee, Tannista & Siebert, Ralph, 2017. "Dynamic impact of uncertainty on R&D cooperation formation and research performance: Evidence from the bio-pharmaceutical industry," Research Policy, Elsevier, vol. 46(7), pages 1255-1271.
  28. Dubois, Pierre & Gandhi, Ashvin & Vasserman, Shoshana, 2022. "Bargaining and International Reference Pricing in the Pharmaceutical Industry," Research Papers 3889, Stanford University, Graduate School of Business.
  29. Kjell Hausken & Mthuli Ncube, 2020. "Game theoretic analysis of persons, the pharmaceutical industry, and donors in disease contraction and recovery," Palgrave Communications, Palgrave Macmillan, vol. 7(1), pages 1-17, December.
  30. IOSIF, Alina Natalia & GURGU, ELENA, 2019. "Provisions Concerning The Organization Of Events For The Promotion Of Products On The Pharmaceutical Market In Romania," Annals of Spiru Haret University, Economic Series, Universitatea Spiru Haret, vol. 19(3), pages 111-126.
  31. Aggarwal, Mayank & Chakrabarti, Anindya S. & Chatterjee, Chirantan & Higgins, Matthew J., 2023. "Research and market structure: Evidence from an antibiotic-resistant pathogenic outbreak," Research Policy, Elsevier, vol. 52(1).
  32. Dranove, David & Garthwaite, Craig & Heard, Christopher & Wu, Bingxiao, 2022. "The economics of medical procedure innovation," Journal of Health Economics, Elsevier, vol. 81(C).
  33. Aghamolla, Cyrus & Thakor, Richard T., 2022. "IPO peer effects," Journal of Financial Economics, Elsevier, vol. 144(1), pages 206-226.
  34. Sam Peltzman, 2022. "“The theory of economic regulation” after 50 years," Public Choice, Springer, vol. 193(1), pages 7-21, October.
  35. Zhili Tian & Ralph Siebert, 2020. "Dynamic Effects of Licensing and Knowledge Transfer across Research Stages: Evidence from the Pharmaceutical Industry," CESifo Working Paper Series 8311, CESifo.
  36. Ian Goldin & Pantelis Koutroumpis & François Lafond & Julian Winkler, 2024. "Why Is Productivity Slowing Down?," Journal of Economic Literature, American Economic Association, vol. 62(1), pages 196-268, March.
  37. Margaret K. Kyle, 2019. "The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals," NBER Chapters, in: Innovation Policy and the Economy, Volume 20, pages 95-123, National Bureau of Economic Research, Inc.
  38. Alice M. Ellyson & Anirban Basu, 2021. "Do pharmaceutical prices rise anticipating branded competition?," Health Economics, John Wiley & Sons, Ltd., vol. 30(5), pages 1070-1081, May.
  39. Gold, E. Richard, 2021. "The fall of the innovation empire and its possible rise through open science," Research Policy, Elsevier, vol. 50(5).
  40. Alfred B. Ordman, 2022. "When Will the FDA Do What Is in People’s Best Interests?," American Journal of Economics and Sociology, Wiley Blackwell, vol. 81(4), pages 721-751, September.
  41. Oscar à lvarez & Fernández Martínez Juan Luis, 2019. "The Importance of Biological Invariance in Drug Design," Biomedical Journal of Scientific & Technical Research, Biomedical Research Network+, LLC, vol. 18(1), pages 13211-13212, May.
  42. Itamar Megiddo & Dusan Drabik & Tim Bedford & Alec Morton & Justus Wesseler & Ramanan Laxminarayan, 2019. "Investing in antibiotics to alleviate future catastrophic outcomes: What is the value of having an effective antibiotic to mitigate pandemic influenza?," Health Economics, John Wiley & Sons, Ltd., vol. 28(4), pages 556-571, April.
  43. Edouard Debonneuil & Anne Eyraud-Loisel & Frédéric Planchet, 2018. "Can Pension Funds Partially Manage Longevity Risk by Investing in a Longevity Megafund?," Risks, MDPI, vol. 6(3), pages 1-27, July.
  44. Fabian Gaessler & Stefan Wagner, 2022. "Patents, Data Exclusivity, and the Development of New Drugs," The Review of Economics and Statistics, MIT Press, vol. 104(3), pages 571-586, May.
  45. David B. Ridley & Chung-Ying Lee, 2020. "Does Medicare Reimbursement Drive Up Drug Launch Prices?," The Review of Economics and Statistics, MIT Press, vol. 102(5), pages 980-993, December.
  46. Joan Costa‐Font & Rosella Levaggi, 2020. "Innovation, aging, and health care: Unraveling “silver” from “red” herrings?," Health Economics, John Wiley & Sons, Ltd., vol. 29(S1), pages 3-7, October.
  47. Shi Chen & Ted Klastorin & Michael R. Wagner, 2021. "Designing practical coordinating contracts in decentralized projects," Naval Research Logistics (NRL), John Wiley & Sons, vol. 68(2), pages 183-198, March.
  48. Alba C. Rojas-Cordova & Niyousha Hosseinichimeh, 2018. "Trial Termination and Drug Misclassification in Sequential Adaptive Clinical Trials," Service Science, INFORMS, vol. 10(3), pages 354-377, September.
  49. Thakur-Wernz, Pooja & Bruyaka, Olga & Contractor, Farok, 2020. "Antecedents and relative performance of sourcing choices for new product development projects," Technovation, Elsevier, vol. 90.
  50. Roger D. Blair & Anita N. Walsh, 2020. "Method-of-Use Patents, Appropriability, and Antitrust Policy," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 56(4), pages 651-666, June.
  51. Fossett, Sarah J. & Wunnava, Phanindra V., 2017. "Active Ingredients: Exploring the Key Factors Affecting the Rising Cost of Developing New Drugs," IZA Discussion Papers 10817, Institute of Labor Economics (IZA).
  52. Billette de Villemeur, Etienne & Versaevel, Bruno, 2019. "One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry," Journal of Health Economics, Elsevier, vol. 65(C), pages 260-283.
  53. Chen, Xu & Yang, Huan & Wang, Xiaojun, 2019. "Effects of price cap regulation on the pharmaceutical supply chain," Journal of Business Research, Elsevier, vol. 97(C), pages 281-290.
  54. Joshua Krieger & Danielle Li & Dimitris Papanikolaou, 2022. "Missing Novelty in Drug Development," The Review of Financial Studies, Society for Financial Studies, vol. 35(2), pages 636-679.
  55. Casey B. Mulligan, 2020. "Economic Activity and the Value of Medical Innovation during a Pandemic," NBER Working Papers 27060, National Bureau of Economic Research, Inc.
  56. Ute Laermann-Nguyen & Martin Backfisch, 2021. "Innovation crisis in the pharmaceutical industry? A survey," SN Business & Economics, Springer, vol. 1(12), pages 1-37, December.
  57. Anna Chorniy & James Bailey & Abdulkadir Civan & Michael Maloney, 2021. "Regulatory review time and pharmaceutical research and development," Health Economics, John Wiley & Sons, Ltd., vol. 30(1), pages 113-128, January.
  58. Panos Kouvelis & Joseph Milner & Zhili Tian, 2017. "Clinical Trials for New Drug Development: Optimal Investment and Application," Manufacturing & Service Operations Management, INFORMS, vol. 19(3), pages 437-452, July.
  59. Crego, Julio & Kárpáti, Daniel & Kværner, Jens & Renneboog, Luc, 2022. "The Economic Value of Eliminating Diseases," Other publications TiSEM 8b51764f-3ccd-4bb8-9da1-4, Tilburg University, School of Economics and Management.
  60. Romasanta, Angelo K.S. & van der Sijde, Peter & de Esch, Iwan J.P., 2022. "Absorbing knowledge from an emerging field: The role of interfacing by proponents in big pharma," Technovation, Elsevier, vol. 110(C).
  61. Uluc Aysun, 2023. "Technology diffusion and international business cycles," Working Papers 2023-02, University of Central Florida, Department of Economics.
  62. Vincenzo Atella & Joanna Kopinska, 2018. "New Technologies and Costs," CEIS Research Paper 442, Tor Vergata University, CEIS, revised 09 Aug 2018.
  63. Jobjörnsson, Sebastian & Forster, Martin & Pertile, Paolo & Burman, Carl-Fredrik, 2016. "Late-stage pharmaceutical R&D and pricing policies under two-stage regulation," Journal of Health Economics, Elsevier, vol. 50(C), pages 298-311.
  64. Hassan Heidari & Arash Refah Kahriz & Yousef Mohammadzadeh, 2019. "Stock market behavior of pharmaceutical industry in Iran and macroeconomic factors," Economic Change and Restructuring, Springer, vol. 52(3), pages 255-277, August.
  65. Concepta McManus & Abilio Afonso Baeta Neves & Alvaro Toubes Prata, 2021. "Scientific publications from non-academic sectors and their impact," Scientometrics, Springer;Akadémiai Kiadó, vol. 126(11), pages 8887-8911, November.
  66. Gergő Tömöri & Vilmos Lakatos & Bernadett Béresné Mártha, 2021. "The Effect of Financial Risk Taking on Profitability in the Pharmaceutical Industry," Economies, MDPI, vol. 9(4), pages 1-14, October.
  67. Gregor Dorfleitner & Felix Rößle, 2018. "The financial performance of the health care industry: a global, regional and industry specific empirical investigation," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(4), pages 585-594, May.
  68. Jorge Vieira & Rui Frade & Raquel Ascenso & Filipa Martinho & Domingos Martinho, 2021. "Determinants of Internationalization as Levers for Sustainability: A Study of the Portuguese Pharmaceutical Sector," Sustainability, MDPI, vol. 13(17), pages 1-16, August.
  69. Du, Weijian & Li, Mengjie & Wang, Faming, 2020. "Role of rent-seeking or technological progress in maintaining the monopoly power of energy enterprises: An empirical analysis based on micro-data from China," Energy, Elsevier, vol. 202(C).
  70. Sanzenbacher, Geoffrey T. & Wettstein, Gal, 2020. "Drug insurance and the strategic behavior of drug manufacturers: Evergreening and generic entry after Medicare Part D," Journal of Health Economics, Elsevier, vol. 72(C).
  71. Stig Johan Wiklund, 2019. "A modelling framework for improved design and decision-making in drug development," PLOS ONE, Public Library of Science, vol. 14(8), pages 1-22, August.
  72. Jacopo Umberto Verga & Matthew Huff & Diarmuid Owens & Bethany J. Wolf & Gary Hardiman, 2022. "Integrated Genomic and Bioinformatics Approaches to Identify Molecular Links between Endocrine Disruptors and Adverse Outcomes," IJERPH, MDPI, vol. 19(1), pages 1-24, January.
  73. Ruoxuan Xiong & Susan Athey & Mohsen Bayati & Guido Imbens, 2019. "Optimal Experimental Design for Staggered Rollouts," Papers 1911.03764, arXiv.org, revised Sep 2023.
  74. Angelo Kenneth S. Romasanta & Peter Sijde & Jacqueline Muijlwijk-Koezen, 2020. "Innovation in pharmaceutical R&D: mapping the research landscape," Scientometrics, Springer;Akadémiai Kiadó, vol. 125(3), pages 1801-1832, December.
  75. Viswanath Pingali & Neelima Das, 2021. "Rare Diseases Require Support Too," Vikalpa: The Journal for Decision Makers, , vol. 46(2), pages 129-134, June.
  76. Camille Loir & Bertrand Groslambert, 2023. "The impact of innovation on the profitability of the biotech industry," Economics Bulletin, AccessEcon, vol. 43(3), pages 1286-1297.
  77. Kristopher J. Hult, 2018. "Measuring the Potential Health Impact of Personalized Medicine: Evidence from Multiple Sclerosis Treatments," NBER Chapters, in: Economic Dimensions of Personalized and Precision Medicine, pages 185-216, National Bureau of Economic Research, Inc.
  78. Benjamin Speich & Nadine Schur & Dmitry Gryaznov & Belinda von Niederhäusern & Lars G Hemkens & Stefan Schandelmaier & Alain Amstutz & Benjamin Kasenda & Christiane Pauli-Magnus & Elena Ojeda-Ruiz & Y, 2019. "Resource use, costs, and approval times for planning and preparing a randomized clinical trial before and after the implementation of the new Swiss human research legislation," PLOS ONE, Public Library of Science, vol. 14(1), pages 1-16, January.
  79. David Mhlanga, 2022. "The Role of Artificial Intelligence and Machine Learning Amid the COVID-19 Pandemic: What Lessons Are We Learning on 4IR and the Sustainable Development Goals," IJERPH, MDPI, vol. 19(3), pages 1-22, February.
  80. Casey B. Mulligan, 2020. "Economic Activity and the Value of Medical Innovation during a Pandemic," Working Papers 2020-48, Becker Friedman Institute for Research In Economics.
  81. Yin, Nina, 2023. "Pharmaceuticals, incremental innovation and market exclusivity," International Journal of Industrial Organization, Elsevier, vol. 87(C).
  82. Michael D. Frakes & Melissa F. Wasserman, 2020. "Investing in Ex Ante Regulation: Evidence from Pharmaceutical Patent Examination," NBER Working Papers 27579, National Bureau of Economic Research, Inc.
  83. Brandão, Luiz E. & Fernandes, Gláucia & Dyer, James S., 2018. "Valuing multistage investment projects in the pharmaceutical industry," European Journal of Operational Research, Elsevier, vol. 271(2), pages 720-732.
  84. Lo, Andrew W. & Thakor, Richard T., 2023. "Financial intermediation and the funding of biomedical innovation: A review," Journal of Financial Intermediation, Elsevier, vol. 54(C).
  85. Volker Grossmann, 2021. "Medical Innovations and Ageing: A Health Economics Perspective," CESifo Working Paper Series 9387, CESifo.
  86. Dai, Rong & Watal, Jayashree, 2021. "Product patents and access to innovative medicines," Social Science & Medicine, Elsevier, vol. 291(C).
  87. Paolo Pertile & Simona Gamba & Martin Forster, 2018. "Free-Riding in Pharmaceutical Price Regulation: Theory and Evidence," Discussion Papers 18/04, Department of Economics, University of York.
  88. Szabolcs Nagy & Sergey U. Chernikov & Ekaterina Degtereva, 2022. "The Impact of the Pharmaceutical Industry on the Innovation Performance of European Countries," Papers 2212.13839, arXiv.org.
  89. Benoit Playe & Chloé-Agathe Azencott & Véronique Stoven, 2018. "Efficient multi-task chemogenomics for drug specificity prediction," PLOS ONE, Public Library of Science, vol. 13(10), pages 1-34, October.
  90. Arisa Djurian & Tomohiro Makino & Yeongjoo Lim & Shintaro Sengoku & Kota Kodama, 2020. "Trends of Business-to-Business Transactions to Develop Innovative Cancer Drugs," Sustainability, MDPI, vol. 12(14), pages 1-14, July.
  91. Debdatta Saha & T. M. Vasuprada, 2021. "Understanding the Trade-offs in Drug Development: Retrospective on Lessons from the Early Phase of the COVID-19 Pandemic," Journal of Developing Societies, , vol. 37(3), pages 329-362, September.
  92. Bai Liu & Shuyan Guo & Bin Ding, 2020. "Technical Blossom in Medical Care: The Influence of Big Data Platform on Medical Innovation," IJERPH, MDPI, vol. 17(2), pages 1-17, January.
  93. Perin, Fernanda & Paranhos, Julia, 2022. "The Internationalisation of the Large Brazilian Pharmaceutical Companies: Challenges, Competitive Advantages and Strategies," CAFE Working Papers 20, Centre for Accountancy, Finance and Economics (CAFE), Birmingham City Business School, Birmingham City University.
  94. Hu, Mei-Ying & Lu, You-Xun & Lai, Ching-chong, 2023. "Patent term extensions and commercialization lags in the pharmaceutical industry: A growth-theoretic analysis," Journal of Macroeconomics, Elsevier, vol. 76(C).
  95. Henry Grabowski & Carlos Brain & Anna Taub & Rahul Guha, 2017. "Pharmaceutical Patent Challenges: Company Strategies and Litigation Outcomes," American Journal of Health Economics, MIT Press, vol. 3(1), pages 33-59, Winter.
  96. Enes Işık & Özgür Orhangazi, 2022. "Profitability and drug discovery," Industrial and Corporate Change, Oxford University Press and the Associazione ICC, vol. 31(4), pages 891-904.
  97. Pintado T & Ruiz Capillas C & Herrero AM, 2019. "New Lipid Materials Based on Chia Emulsion Gels: Application in Meat Products," Biomedical Journal of Scientific & Technical Research, Biomedical Research Network+, LLC, vol. 18(1), pages 13215-13218, May.
  98. Heyoung Yang & Hyuck Jai Lee, 2018. "Long-Term Collaboration Network Based on ClinicalTrials.gov Database in the Pharmaceutical Industry," Sustainability, MDPI, vol. 10(2), pages 1-14, January.
  99. Clancy, Matthew S. & Sneeringer, Stacy E., 2018. "How Much Does it Cost to Induce R&D in Animal Health?," 2018 Annual Meeting, August 5-7, Washington, D.C. 273865, Agricultural and Applied Economics Association.
  100. Liang (Leon) Xu & Hui Zhao & Nicholas C. Petruzzi, 2021. "Inducing Compliance with Postmarket Studies for Drugs Under FDA’s Accelerated Approval Pathway," Manufacturing & Service Operations Management, INFORMS, vol. 23(1), pages 170-190, 1-2.
  101. Veronika Fenyves & Balazs Nyul & Krisztina Dajnoki & Zoltan Bacs & Gergo Tomori, 2019. "Profitability of Pharmaceutical Companies in the Visegrád Countries," Montenegrin Journal of Economics, Economic Laboratory for Transition Research (ELIT), vol. 15(4), pages 99-111.
  102. Leila Agha & Soomi Kim & Danielle Li, 2020. "Insurance Design and Pharmaceutical Innovation," NBER Working Papers 27563, National Bureau of Economic Research, Inc.
  103. Troy J. Scott & Nicholas S. Vonortas, 2021. "Microgravity protein crystallization for drug development: a bold example of public sector entrepreneurship," The Journal of Technology Transfer, Springer, vol. 46(5), pages 1442-1461, October.
  104. Stefano Capri, 2020. "High prices of new drugs: we are ready to do whatever it takes," LIUC Papers in Economics 2020-8, Cattaneo University (LIUC).
  105. Samira Guennif, 2022. "Capture and passive predation in times of COVID-19 pandemic," Public Choice, Springer, vol. 193(3), pages 163-186, December.
  106. Christian Corsi & Antonio Prencipe, 2019. "DOES CEO PROMOTE INNOVATION IN SMEs? A COMPARISON BETWEEN INTERNAL AND EXTERNAL CEO," International Journal of Innovation Management (ijim), World Scientific Publishing Co. Pte. Ltd., vol. 23(05), pages 1-19, June.
  107. Andres Alban & Stephen E. Chick & Martin Forster, 2023. "Value-Based Clinical Trials: Selecting Recruitment Rates and Trial Lengths in Different Regulatory Contexts," Management Science, INFORMS, vol. 69(6), pages 3516-3535, June.
  108. Natalia Leonidovna Borscheva & Yulia Vyacheslavovna Fedorova & Marina Ivanovna Glukhova & Guzal Ilgizovna Islamova, 2020. "Impact of innovative activity of organizations on the development of pharmaceutical industry: a case study," Entrepreneurship and Sustainability Issues, VsI Entrepreneurship and Sustainability Center, vol. 7(4), pages 3001-3015, June.
  109. Watal, Jayashree & Dai, Rong, 2019. "Product patents and access to innovative medicines in a post-trips-era," WTO Staff Working Papers ERSD-2019-05, World Trade Organization (WTO), Economic Research and Statistics Division.
  110. Unsal, Omer & Rayfield, Blake, 2019. "Institutional investors and medical innovation," The Quarterly Review of Economics and Finance, Elsevier, vol. 74(C), pages 190-205.
  111. Goel, Rajeev K. & Nelson, Michael A. & Goel, Viraat Y., 2021. "COVID-19 vaccine rollout—scale and speed carry different implications for corruption," Journal of Policy Modeling, Elsevier, vol. 43(3), pages 503-520.
  112. Simona Gamba & Laura Magazzini & Paolo Pertile, 2019. "R&D and market size: who benefits from orphan drug regulation?," Working Papers 09/2019, University of Verona, Department of Economics.
  113. Paweł Żelewski & Michał Wojna & Katarzyna Sygit & Elżbieta Cipora & Izabela Gąska & Mateusz Niemiec & Mateusz Kaczmarski & Tomasz Banaś & Beata Karakiewicz & Artur Kotwas & Paulina Zabielska & Olga Pa, 2022. "Comparison of US and EU Prices for Orphan Drugs in the Perspective of the Considered US Orphan Drugs Act Modifications and Discussed Price-Regulation Mechanisms Adjustments in US and European Union," IJERPH, MDPI, vol. 19(19), pages 1-17, September.
  114. Kyle, Margaret K., 2022. "Incentives for pharmaceutical innovation: What’s working, what’s lacking," International Journal of Industrial Organization, Elsevier, vol. 84(C).
  115. Maureen McKelvey & Bastian Rake, 2020. "Exploring scientific publications by firms: what are the roles of academic and corporate partners for publications in high reputation or high impact journals?," Scientometrics, Springer;Akadémiai Kiadó, vol. 122(3), pages 1323-1360, March.
  116. Mrityunjay Kumar & Ayesha Fatma & Nalin Bharti, 2022. "Access to Medicines and Medical Equipment during COVID-19: Searching Compatibility between the WTO and the WHO," India Quarterly: A Journal of International Affairs, , vol. 78(1), pages 68-87, March.
  117. Ralph Siebert & Zhili Tian, 2020. "Dynamic Mergers Effects on R&D Investments and Drug Development across Research Phases in the Pharmaceutical Industry," CESifo Working Paper Series 8303, CESifo.
  118. Venkatanarayana Motkuri & Rudra Narayan Mishra, 2020. "Pharmaceutical Market and Drug Price Policy in India," Review of Development and Change, , vol. 25(1), pages 30-53, June.
  119. Sang-Min Park & Nicholas S. Vonortas, 2023. "Translational research: from basic research to regional biomedical entrepreneurship," Small Business Economics, Springer, vol. 60(4), pages 1761-1783, April.
  120. Tannista Banerjee & Ralph Siebert, 2017. "The Impact of R&D Cooperations and Mergers in Pharmaceuticals on Research Activities and Drugs Offered on the Market," Southern Economic Journal, John Wiley & Sons, vol. 84(1), pages 202-228, July.
  121. Guido Thommes & Martin Oliver Sailer & Nicolas Bonnet & Alex Carlton & Juan J. Abellan & Veronique Robert, 2022. "Awareness and use of quantitative decision-making methods in pharmaceutical development," Papers 2203.00684, arXiv.org.
  122. Ekaterina Galkina Cleary & Laura M McNamee & Skyler de Boer & Jeremy Holden & Liam Fitzgerald & Fred D Ledley, 2021. "Comparing long-term value creation after biotech and non-biotech IPOs, 1997–2016," PLOS ONE, Public Library of Science, vol. 16(1), pages 1-13, January.
  123. L. M. Daphne Yiu & Hugo K. S. Lam & Andy C. L. Yeung & T. C. E. Cheng, 2020. "Enhancing the Financial Returns of R&D Investments through Operations Management," Production and Operations Management, Production and Operations Management Society, vol. 29(7), pages 1658-1678, July.
  124. Whichello, Chiara & Bywall, Karin Schölin & Mauer, Jonathan & Stephen, Watt & Cleemput, Irina & Pinto, Cathy Anne & van Overbeeke, Eline & Huys, Isabelle & de Bekker-Grob, Esther W. & Hermann, Richard, 2020. "An overview of critical decision-points in the medical product lifecycle: Where to include patient preference information in the decision-making process?," Health Policy, Elsevier, vol. 124(12), pages 1325-1332.
  125. Vishal Ahuja & John R. Birge, 2020. "An Approximation Approach for Response-Adaptive Clinical Trial Design," INFORMS Journal on Computing, INFORMS, vol. 32(4), pages 877-894, October.
  126. Motkuri, Venkatanarayana & Mishra, Rudra Narayana, 2018. "National Drug Policy Face-off: Some Notes Justifying the Regulations and Drug Price Control Regime in India," MPRA Paper 84318, University Library of Munich, Germany.
  127. Tobias Basse & Christoph Schwarzbach & J.-Matthias Schulenburg, 2023. "Dividend policy issues in the European pharmaceutical industry: new empirical evidence," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(5), pages 803-816, July.
  128. Stephen E. Chick & Noah Gans & Özge Yapar, 2022. "Bayesian Sequential Learning for Clinical Trials of Multiple Correlated Medical Interventions," Management Science, INFORMS, vol. 68(7), pages 4919-4938, July.
  129. Stacy Sneeringer & Matt Clancy, 2020. "Incentivizing New Veterinary Pharmaceutical Products to Combat Antibiotic Resistance," Applied Economic Perspectives and Policy, John Wiley & Sons, vol. 42(4), pages 653-673, December.
  130. Pinar Keskinocak & Nicos Savva, 2020. "A Review of the Healthcare-Management (Modeling) Literature Published in Manufacturing & Service Operations Management," Manufacturing & Service Operations Management, INFORMS, vol. 22(1), pages 59-72, January.
IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.